

IT **ATTTRs**  
Colorado



Implementing Technology,  
Medication Assisted Treatment,  
Team Training, and Resources

**PRIMARY CARE PRACTICE TEAM TRAINING**

---

**Module 4**  
**Stabilization & Maintenance and Special Populations**



Copyright 2018 Regents of the University of Colorado. All Rights Reserved. For permission to use content for purposes other than IT MATTRs Practice Team Training, please contact [ITMATTRs@colorado.edu](mailto:ITMATTRs@colorado.edu)





**Practice team training modules**

IT **ATTTRs**  
Colorado

1. Opioids, Receptors, Colorado, and You
2. The Patient: Your role preparing the patient for MAT with buprenorphine
3. The Practice: Supporting and providing MAT
4. *The Practice: Stabilization & Maintenance and Special Populations*








IT **ATTTRs**  
Colorado

**MODULE 4**

- Practice MAT care during Stabilization and Maintenance
- Insurance and billing
- Duration of treatment and relapse
- Special populations

**Buprenorphine treatment**

IT **ATTTRs**



Induction
Stabilization
Maintenance




## Treatment with Buprenorphine: Why are we doing this?

IT ATTRs





**REMEMBER**

To find the right dose of buprenorphine at which the patient:

- Has no opioid withdrawal symptoms
- Experiences decreased cravings
- Has minimal/no side effects
- Return to usual activities (work, school, family)
- Discontinues or markedly reduces use of other opioids

SNOCAP

Department of Family Medicine  
UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CENTER

## MAT DURING STABILIZATION AND MAINTENANCE

SNOCAP

Department of Family Medicine  
UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CENTER

IT ATTRs  
Colorado

Department of Family Medicine  
UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CENTER

## Stabilization and Maintenance

IT ATTRs  
Colorado

### Stabilization

- Lasts for 4-12 weeks, as patient's dose is adjusted and other opioid use (hopefully) resolves
- Contact: tailored to patient's needs. Daily, weekly, monthly as patient becomes more stable
- Behavioral health care is introduced
- Practice checks the **Prescription Drug Monitoring Program**

*Don't expect abstinence after first dose of buprenorphine*

### Maintenance

- Withdrawal symptoms are resolved, cravings are decreasing, side effects are managed
- Patient is able to start dealing with other stuff that contributed to having OUD in the first place
- Contact: Continue monthly visits typical for stable patients. We recommend 12 months, or more.

SNOCAP

Department of Family Medicine  
UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CENTER

## Primary care management: **medical care team**

IT ATTRs  
Colorado

- Contact: every 2-4 weeks initially, monthly once stabilized
- Monitor medication compliance (frequency, sublingual technique)
- Monitor patients' drug use (tobacco, alcohol, and other drugs)
- Encourage abstinence from illicit opioids
- Ask about cravings/triggers
- Identify and treat side effects (constipation, sedation)
- Discuss safe storage
- Ask your patient about social support, family, relationships
- Check [SuboxoneRx.com](#) for outside medications and providers
- Be aware of and/or provide referral for housing, employment, legal issues...

### Acknowledge progress!

#### Pill/Film Count = Standard Care:

- Have patient bring in medication supply
- Confirm patient ID and fill date on bottle/box
- Have patient count pills/film in front of staff member
- Confirm all tablets/film are identical
- Compare current quantity with expected quantity

SNOCAP

Department of Family Medicine  
UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CENTER

Primary care management: **behavioral care team**

**Behavioral health takes many forms – tailor to patient's need**

- “Supportive care”: informal counseling, motivational interviewing, goal setting, etc.
- Individual, group, and/or family counseling; peer counseling
- Self-help groups
- Cognitive behavioral therapy (CBT / DBT)
- Addiction counseling
- Lifestyle changes that support recovery and to avoid potential triggers of drug use
- Relapse prevention
- Increased services for higher psychiatric severity patients

Lots of options



Primary care management: **behavioral care team**

- Stabilize patient with buprenorphine.
- Discuss behavioral health options. (Evidence does not support mandated counseling.)
- During MAT Review Appointment, acknowledge that behavioral health care can play an important role in successful MAT.
  - If needs are known prior to Induction, consider placing a referral as a pro-active step, especially if the referral process takes a while.
  - Inform patient that behavioral health care needs will be discussed throughout the MAT.



Setting and monitoring treatment goals



- Discuss and document specific, realistic goals
- Set specific time periods
- Document progress on goals at each visit – celebrate!
- Examples:
  - Achieve abstinence from illicit and non-prescribed drugs
  - Meet with clinician
  - Attend meetings
  - Complete job applications



Urine drug testing (UDT)

[Tru#vnr#iprg0shvfuswrc#ofl#guxjv](#)

- \*\*\*\*Use UDT as a way to support your relationship with your patient.\*\*\*
- \*\*\*\* Know how your practice will use results.\*\*\*
- Part of standard of care for:
  - Monitoring for ongoing opioid use and use of non-opioids
  - Monitoring for adherence to buprenorphine administration
  - Identifying those who may need higher level of care
- Conduct every 1-2 weeks early in treatment; monthly after
- Know how your practice will use results. You want to find buprenorphine and nothing else! If there's no BUP, the patient might be diverting (selling) medication.



## Insurance (Medication Coverage)

- MAT is covered for moderate and severe opioid use disorder
- Medicaid:
  - Covers buprenorphine treatment (office-based opioid treatment)
  - Requires pre-certification (quick process, easy)\*; valid for a year
    - \*House Bill 18-1007 requires coverage without prior authorization for a five-day supply of FDA-approved drugs for a first request within a 12-month period
- Medicare:
  - Covers buprenorphine treatment, but prior authorization may be more difficult depending on insurer.
  - Part D and Advantage Plans
- Private insurers: almost all insurances cover prescription but there is variation by payer, patient's plan

## Insurance (Medication Coverage)

- Questions to ask: Does the patient's insurance cover...
  - MAT in the primary care setting?
  - Buprenorphine?
  - Behavioral Health treatment? Beware of carve outs!
  - Lab services?
  - Any duration of treatment (no restrictions)?
- Anticipate prior approval procedures
  - Collect forms from each payer and submit prior to prescription fill
  - Consider cash for first few days supply
  - Monitor patient's pharmacy benefits
  - 340B coverage in some Community Health Centers

## Insurance (continued)

- Cost of suboxone: approximately \$1.00 - \$1.50 for every mg; buprenorphine (alone) cheaper
- Uninsured pts can apply for a patient assistance program (PAP) for buprenorphine
  - Free medications for up to one year
  - Each prescriber is allowed three patients on this program.
  - \*\*\* Coupons are available for eligible patients at: <http://www.suboxone.com/treatment-plan/savings-card?cid=subx>
  - Or consider generic tabs (much cheaper, \$1.50 for mono-product and \$2.50 for combo)

## Relapse

- Estimated relapse in drug addiction: 40-60%, can be higher in first year
  - Does not mean patient is failing medical treatment!
  - Does mean patient needs support to stay in treatment, keep trying, and possibly make some refinements (e.g., social exposures, family to monitor taking medication)
- Estimated long-term adherence to therapy for chronic illness overall: 50%
- Estimated relapse in other chronic diseases:
  - Hypertension: 50-70%
  - Asthma: 50-70%

## Relapse

F r q v l g h u # j r d o v # r # i h d v p h q w

- Abstinence from illicit and non-prescribed drugs
- Harm reduction
- Engage/retain in treatment
- Facilitate and accelerate behavior change
- Treatment/prevention of medical co-morbidities
- Identification and treatment of psychiatric co-morbidities
- Decrease negative impact on society
- *To what degree is patient meeting treatment goals?*

## Buprenorphine discontinuation

- First question is "Why discontinue?"
- Explore reasons for discontinuation with patient and significant others
- Naltrexone therapy might be considered (deterrent; "sick high")
- Psychosocial treatments should continue
- Patients should be followed by provider after discontinuation
- Patients should be told they can resume buprenorphine treatment if cravings, lapses, or relapses occur



Lauren

63 # j r i # p d d # z l k # s u r # k l w c u | # r # i h d v p h q w # s l r y # k v h #  
g l n g h u # k d v i e h h g f g r l j # z h o k g # e x s u h q r u s k l g h z d o r ( r q h #  
i n u # # r q w e v # z l k # p s u r y n p h q w # i # k g f w r q # i g g # x d d v # r # i h # #  
U h w a q v # i r u # z x w l g # i r a z # k s # l s s r l y p h q w # i g g # p h q w e q v # k d v #  
k h u # i v # h u i g # z d v # # z h n r v # i j r # # s r x e w # k h # e r x g # e h #  
s u h j q d q v # i v # # k h # i g g # k h u # o v e d g # e u l f w e # h # k h # k | w p #  
p h w e r g # k h u # c u l g # s u h j q d q f | # h w # e r p h v # e d f n # s r v l d y h # # / k h #  
z d q w # z # h q r z # # i h # k h # k r x g # w r s # k h u # e x s u h q r u s k l g h z d o r ( r q h #  
l p # h g l h n d # i h # k h u # o v e d g # # h d i j # k h u # z # g r l



## CONSIDERATIONS FOR SPECIAL POPULATIONS





## Pregnancy: maintenance therapy is standard of care

- Methadone and buprenorphine (both category C) are safe and effective treatment options
- Maintenance therapy is standard of care

### Maternal Benefits

- 70% reduction in overdose related deaths
- Decrease in risk of HIV, Hep B, and Hep C
- Increased engagement in prenatal care and recovery treatment

### Fetal Benefits

- Uhgxfhv#ioxfwcdwrcv#lqjp dwnuqddisrlg#  
dyho/#hgxflj#hwd#wuhvv
- Ghfuhdvh#g#lqwxwhugh#hwdghp lvh
- Ghfuhdvh#g#lqwxwhugh#juz w#hvwulfwrcq
- Ghfuhdvh#g#shwhup #ghdylul

Fischer et al. 1998, 1999; Jones et al. 2010



## Management of newly pregnant patient

- For women on buprenorphine/naloxone who become pregnant:
  - Maintain patient on buprenorphine/naloxone
  - Buprenorphine monotherapy is also safe to use, and should be continued if used prior to pregnancy
  - May need to increase medication dose during pregnancy
- For women who need to start treatment:
  - Induce to start treatment? Yes, put patient into withdrawal.
  - Start first dose at lower COWS score (6-7 vs 12). Start with higher dose (8 mg vs 4 mg).



## Pharmacologic treatment with adolescents

- Pharmacologic therapy is recommended for adolescents with severe OUD.
- Buprenorphine is considered first line treatment. Most methadone clinics cannot admit patients under 18 years old.
- Impact on the developing brain is unknown - exposure to heroin and other drugs is worse than the possible effects of buprenorphine.



## Co-Morbidities

## Medical Co-morbidities

- Persons with OUD frequently have or are at risk of other co-morbid medical conditions.
- Office-based buprenorphine treatment provides an opportunity to combine substance use treatment with medical care.
- Know your patients' Hepatitis C status
  - 70-90% of people who inject drugs (e.g., heroin) have Hep C
  - ~30% are less than 30 years old
  - Hep C-related deaths outnumber deaths due to HIV.
  - Recommendation is to test everyone for Hep C.

## Psychiatric Co-morbidities

Substance-induced: Disorders **related to the use** of psychoactive substance; typically resolve with sustained abstinence.

- Patient's history suggests symptoms occur only when he/she is actively using substances.
- Goal should be sustained abstinence followed by re-evaluation of symptoms.

Independent: Disorders **not related to the use** of psychoactive substance but rather arise during times of *abstinence*)


- Family history of the disorder may exist.
- Goal of substance use disorder treatment should still be cessation of substance use, but treatment must also address psychiatric symptoms simultaneously.

## General treatment principles

- Patients with opioid use disorder and independent depressive, anxiety, or stress disorders (PTSD) can respond to medication (typically antidepressants) and/or psychotherapy
- Buprenorphine can be a good replacement treatment for benzos.
- Generally avoid use of benzodiazepines

## Resource Reminders

- **COPIC points** (1 for one module, 2 for all four modules)
- **Colorado MAT Virtual Help Desk** ([itmatttrs2@ucdenver.edu](mailto:itmatttrs2@ucdenver.edu))
- **MAT Consultant Panel** (clinicians, staff, and others with MAT expertise)
- **MAT Forums** (twice a month, online, with Consultant Panel)




## MODULE 4 WRAP UP

- Frequent follow-up, monitoring, support, PDMP checking, are important part of MAT.
- Relapse is part of recovery.
- Practices must have the ability to refer for counseling. Behavioral health support is ideal. Studies show good outcomes even with low intensity models.
- Pregnant females and adolescents with OUDs can be managed successfully with buprenorphine.
- OUD is a chronic condition that can co-occur with other medical and psychiatric problems.

## CONGRATULATIONS!

### Are you feeling empowered and equipped to:

- Identify and diagnose patients in need of MAT?
- Understand what your patients will experience with MAT?
- Monitor patients receiving MAT?
- Continue providing care for co-morbidities in context of MAT?
- Implement buprenorphine-based treatment of OUD?



## WHAT'S NEXT

- Review your MATerials Resource Toolkit.
- Schedule follow-up implementation support meetings.
- Let us know what you need.
- Schedule an first induction!

## THANK YOU!

The IT MATTTRs Primary Care and Behavioral Health Team Training curricula were created with support from the Agency for Healthcare Research and Quality (grant number 5R18HS025056-02).

Copyright 2018 Regents of the University of Colorado. All Rights Reserved. For permission to use content for purposes other than IT MATTTRs Practice Team Training, please contact [ITMATTTRs@cuarnschultz.edu](mailto:ITMATTTRs@cuarnschultz.edu).